NEWS

[CAZENOVIA, NY – March 30, 2023] – NCODA University, a division of NCODA that provides top-tier education for future and present oncology pharmacists, has launched a new 15-hour Oncology Basics Course. This first-of-its-kind course will reinforce knowledge of the etiology and pathophysiology of cancer, provide a deeper understanding of commonly used anti-cancer drug classes, and […]

— First Trop-2 Directed ADC to Demonstrate Overall Survival Benefit in HR+/HER2- Metastatic Breast Cancer Patients who had Received Prior Endocrine-based Therapy and at Least Two Chemotherapies — — Trodelvy has Now Improved Survival in both Pre-Treated HR+/HER2- Metastatic Breast Cancer and in Second-Line Metastatic Triple-Negative Breast Cancer —   FOSTER CITY, Calif.–(BUSINESS WIRE)– Gilead Sciences, Inc. […]

FOR IMMEDIATE RELEASE February 23, 2023 MEDIA CONTACT: Katie Edmiston Katie.Edmiston@ncoda.org 813-843-1629   NCODA APPOINTS THREE NEW MEMBERS TO ITS EXECUTIVE COUNCIL CAZENOVIA, NY – NCODA is delighted to announce the expansion of its Executive Council with the appointment of three appointed oncology healthcare leaders: Luis Campos, MD, John Marshall, MD, and Scott Freeswick, PharmD, […]

February 16, 2023 Fresenius Kabi’s first U.S. biosimilar launch Provides accessible, high-quality treatment option for U.S. cancer patients undergoing chemotherapy to reduce the incidence of infection as manifested by febrile neutropenia Strengthens Fresenius Kabi’s heritage in oncology and its commitment to oncology patients The expansion of the company’s global biosimilars portfolio focused on oncology and […]

STATEMENT FROM NCODA LEGISLATIVE & POLICY ADVISORY COMMITTEE (LPAC) Contact: Sarder Sadid, PharmD Phone: (315) 527-8590 Email: sarder.sadid@ncoda.org www.ncoda.org February 16, 2023 On February 9, 2023, US Representatives Earl L. “Buddy” Carter (R-GA), Nanette Barragan (D-CA), Mariannette Miller-Meeks (R-IA), and Diana DeGette (D-CO) introduced the Help Ensure Lower Patient (HELP) Copays Act to the House […]

Taiho Oncology is pleased to announce the commercial availability of LYTGOBI® (futibatinib) tablets. As we are ramping up to full supply, currently the 4mg tablet 35-count DosePak is available for prescribing via Onco360. The remaining two packages, 4mg tablet 28-count DosePak and 4mg tablet 21-count DosePak, will be available on or before April 1, 2023. […]

— First Trop-2 Directed ADC to Demonstrate Overall Survival Benefit in HR+/HER2- Metastatic Breast Cancer Patients who had Received Prior Endocrine-based Therapy and at Least Two Chemotherapies — — Trodelvy has Now Improved Survival in both Pre-Treated HR+/HER2- Metastatic Breast Cancer and in Second-Line Metastatic Triple-Negative Breast Cancer —   FOSTER CITY, Calif.–(BUSINESS WIRE)– Gilead Sciences, Inc. […]

                        ESR1 mutations are present in up to 40% of ER+, HER2- advanced or metastatic breast cancers. ESR1 mutations are a known driver of resistance to standard endocrine therapy, and so far, have been difficult to treat. ORSERDU is the first endocrine innovation in more than 20 years, […]

FOR IMMEDIATE RELEASE January 26, 2023 Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 kevin.scorsone@ncoda.org www.ncoda.org Earlier this year, NCODA and the Patient Access Network (PAN) Foundation co-authored a letter to the United States House of Representatives focused on co-pay accumulator reform through the HELP Copays Act (H.R. 5801). PAN and […]